Compare Crispr Therapeutics AG (CRSP) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Intuit Inc. — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while Intuit Inc. trades at $302.36 (market cap $81.21B). The key difference: Intuit Inc. is far larger — about 16.6× Crispr Therapeutics AG's market cap, and Intuit Inc. pays a 1.82% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Intuit Inc. for 66 Days on average.
| CRSP | INTU | |
|---|---|---|
Market Cap | $4.88B | $81.21B |
Volume | 2,861,747 | 5,165,806 |
Sector | Health | Technology |
52-Week High | $74.92 | $683.39 |
52-Week Low | $44.34 | $255.07 |
Typical Hold Time | 77 Days | 66 Days |
Enterprise Value | $3.30B | $82.43B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Intuit (INTU) trades at $297.24, up 2.56% today, with strong fundamentals including 21.29% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed moving averages, with key support at $293 and resistance at $300. Recent news highlights growth in QuickBooks monetization and AI initiatives, though overshadowed by multiple class action lawsuits filed in early September 2026.
Outlook remains positive with analyst consensus target of $379.68 (27.7% upside), supported by robust revenue growth and expanding margins. Key risks include legal overhang from securities litigation and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, but investors should monitor lawsuit developments and Q3 2026 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
